Estrogen Patch Shortage Stresses Menopause Patients

Women across the United States are reporting ongoing challenges in obtaining estrogen patches for menopause symptom relief. This situation has intensified as demand for hormone replacement therapy has surged, particularly after the FDA removed a "black box warning" from many such products in February 2026. Prescriptions for estrogen patches saw a notable increase from approximately 594,000 in June 2025 to 1.6 million in May 2026.

Doctors and patients are now calling on the FDA to formally recognize a shortage, as the agency's current database does not reflect the pharmacy-level difficulties being experienced. Diane Harris, a patient from Los Angeles, described her stressful search for a consistent supply, even considering pharmacies in Canada. Dr. Suzanne Hackenmiller, an OB-GYN in Arizona, is leading a petition for a formal shortage declaration, believing it could incentivize increased production and market entry.

The American Society of Health-System Pharmacists lists numerous estradiol patch products on its active drug shortage list. Meanwhile, a group of U.S. House Democrats has also urged the FDA to update its federal drug shortage database. The FDA acknowledged reports of access difficulties on September 4, 2026, stating that while availability varies, estradiol transdermal patches remain available and that the agency is working with manufacturers to meet rising demand, recommending patients consult providers for alternatives.